Actively Recruiting
Comparing HDR Brachytherapy Boost Plus SBRT Versus SBRT Alone for High-Risk Prostate Cancer Balancing Cancer Control and Treatment Side Effects
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-08-12
126
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating different radiation therapy methods for people with high-risk prostate cancer to find the best balance between controlling the cancer and minimizing treatment side effects. This study compares the use of HDR brachytherapy combined with stereotactic body radiation therapy SBRT versus SBRT alone. The trial focuses on patients with non-metastatic prostate cancer classified as unfavorable intermediate, high, or very high risk. Participants are randomly assigned to one of two treatment groups one group receives the standard care of HDR brachytherapy plus SBRT, while the other group receives SBRT alone. Both treatments are forms of radiation therapy given to target the prostate cancer. The study aims to assess how these approaches affect symptoms and quality of life. During the study, participants will be monitored for changes in their International Prostate Symptom Score IPSS at three months after treatment to evaluate urinary symptoms. Researchers will also collect other health information throughout the treatment period. The study is expected to continue through July 2030, with scheduled visits and assessments to track participants progress and side effects.
CONDITIONS
Brief Title
Radiation Therapy Approaches for People With Prostate Cancer
Research Team
D
Daniel Gorovets, MD
H
Himanshu Nagar, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here